Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
GlaxoSmithKline PLC ADR(GSK)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GSK
10/02/2026: GSK (1-star) is currently NOT-A-BUY. Pass it for now.
GSK is a focused global biopharmaceutical company specializing in vaccines, HIV therapeutics, and specialty medicines. The company has successfully transitioned into a pure-play entity following the spin-off of its consumer healthcare business, allowing for greater investment in high-margin research areas. Its leading market position in vaccines, particularly with the Arexvy RSV vaccine, represents a primary growth driver. However, the firm faces significant execution risks, including intense competition from generic and biosimilar producers, as well as ongoing challenges related to product patent expirations. GSK is generally well-suited for value-oriented and dividend-focused investors seeking exposure to the stable, large-cap pharmaceutical sector.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | GSK is a mature, slow-growth pharmaceutical firm rather than a high-growth tech or biotech innovator. |
| Momentum investor | Mixed fit | Momentum is conditional on positive regulatory milestones or clinical data that cause significant stock upturns. |
| Value investor | Strong fit | The stock is often viewed as reasonably valued relative to its cash flow generation and dividend stability. |
| Dividend investor | Strong fit | GSK offers a consistent dividend yield, making it an attractive option for income-seeking portfolios. |
| Low-risk investor | Strong fit | As a large-cap pharmaceutical company, it generally exhibits lower volatility compared to smaller, speculative biotech stocks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | Pharmaceutical stocks can fluctuate significantly based on clinical trial results and regulatory decisions. |
| Valuation risk | Low | The stock generally trades within a predictable range relative to sector peers. |
| Competition risk (HIV/Vaccines) | High | GSK faces intense competition from companies like Gilead and Pfizer in its most profitable segments. |
| Business quality | Strong | The firm has a long-standing history of global drug development and market presence. |
| Dividend income | Low / none | The dividend is supported by stable cash flows, though payout ratios remain a factor to monitor. |
| Execution risk | Medium | The company must successfully navigate the complex transition to a pure-play model while maintaining R&D output. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 6.15% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/02/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 94.53B USD | Price to earnings Ratio 15.47 | 1Y Target Price 59.58 |
Price to earnings Ratio 15.47 | 1Y Target Price 59.58 | ||
Volume (30-day avg) 3.2M shares | Beta 0.29 | 52 Weeks Range 41.38 - 60.11 | Updated Date 10/02/2026 |
52 Weeks Range 41.38 - 60.11 | Updated Date 10/02/2026 | ||
Dividends yield (FY) 3.85% | Basic EPS (TTM) 3.05 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Specialty Medicines | HIV drugs, immunology therapies, and oncology medications. | This is the primary revenue driver, focused on high-margin, specialized patient care. |
| Vaccines | Shingrix, Arexvy, and other preventive health vaccines. | A highly defensible business segment with recurring demand and high barriers to entry. |
| General Medicines | Established respiratory and skin treatment portfolios. | Provides reliable, stable cash flow from widely used, mature medical products. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 15.47 | Forward PE 9.77 | Enterprise Value 122.33B | Price to Sales(TTM) 2.85 |
Enterprise Value 122.33B | Price to Sales(TTM) 2.85 | ||
Enterprise Value to Revenue 2.76 | Enterprise Value to EBITDA 9.45 | Shares Outstanding 2.00B | Shares Floating 1.94B |
Shares Outstanding 2.00B | Shares Floating 1.94B | ||
Percent Insiders 0.06 | Percent Institutions 17.48 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
News (Last Updated: 10/02/2026)
About GlaxoSmithKline PLC ADR
Exchange NYSE | Headquarters - | ||
IPO Launch date 1986-07-09 | CEO & Director Mr. Luke Victor Miels | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 66841 | Website https://www.gsk.com |
Full time employees 66841 | Website https://www.gsk.com | ||
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.